JP2000503326A - L―カルノシンを含む腎不全の処置用の組成物 - Google Patents
L―カルノシンを含む腎不全の処置用の組成物Info
- Publication number
- JP2000503326A JP2000503326A JP10520532A JP52053298A JP2000503326A JP 2000503326 A JP2000503326 A JP 2000503326A JP 10520532 A JP10520532 A JP 10520532A JP 52053298 A JP52053298 A JP 52053298A JP 2000503326 A JP2000503326 A JP 2000503326A
- Authority
- JP
- Japan
- Prior art keywords
- meq
- carnosine
- patient
- mmol
- peritoneal dialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010087806 Carnosine Proteins 0.000 title claims abstract description 74
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 title claims abstract description 74
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000001647 Renal Insufficiency Diseases 0.000 title abstract description 25
- 201000006370 kidney failure Diseases 0.000 title abstract description 25
- 239000000385 dialysis solution Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000001990 intravenous administration Methods 0.000 claims abstract description 7
- 238000000502 dialysis Methods 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 238000001631 haemodialysis Methods 0.000 claims description 9
- 230000000322 hemodialysis Effects 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000002357 osmotic agent Substances 0.000 claims description 6
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 210000004303 peritoneum Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 108010016626 Dipeptides Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- -1 polyglucose Chemical compound 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 abstract description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 17
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 11
- 229960002885 histidine Drugs 0.000 description 11
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229940044199 carnosine Drugs 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 208000010444 Acidosis Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000007950 acidosis Effects 0.000 description 7
- 208000026545 acidosis disease Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.慢性腎不全の患者を処置するための方法であって、非経口方法によって治療 有効量のL−カルノシン含有組成物を提供する工程を包含する方法。 2.前記組成物が、静脈注射で患者に投与される、請求項1に記載の方法。 3.前記組成物が、腹膜腔を通じて患者に投与される、請求項1に記載の方法。 4.前記組成物が、アミノ酸の供給源を含む、請求項1に記載の方法。 5.前記組成物が、炭水化物を含む、請求項1に記載の方法。 6.前記組成物が、脂質を含む、請求項1に記載の方法。 7.透析を受ける患者を処置するための方法であって、治療有効量のL−カルノ シン含有組成物を投与する工程を包含する方法。 8.前記組成物が、非経口的に患者に投与される、請求項7に記載の方法。 9.前記組成物が、腹膜腔を通じて患者に投与される、請求項7に記載の方法。 10.前記患者が、血液透析を受ける、請求項7に記載の方法。 11.前記患者が、腹膜透析を受ける、請求項7に記載の方法。 12.前記患者が、ブドウ糖、アミノ酸、ポリペプチド、ポリグルコース、およ びグリセロールからなる群から選ばれる浸透性薬剤を含む腹膜透析溶液を受容す る、請求項7に記載の方法。 13.治療有効量のL−カルノシンを含む、腹膜透析溶液。 14.前記溶液が、おおよそ1.0〜約40mmol/LのL−カルノシンを含む、請求項1 3に記載の腹膜透析溶液。 15.ブドウ糖、アミノ酸、ポリペプチド、ポリグルコース、およびグリセロー ルからなる群から選ばれる浸透性薬剤を含む、請求項13に記載の腹膜透析溶液。 16.以下を含む、請求項13に記載の腹膜透析溶液: おおよそ100〜約150mEq/Lのナトリウム; おおよそ70〜約140mEq/Lの塩素; おおよそ0.0〜約45.0mEq/Lの乳酸塩; おおよそ0.0〜約45.0mEq/Lの重炭酸塩; おおよそ0.0〜約4.0mEq/Lのカルシウム;および おおよそ0.0〜約4.0mEq/Lのマグネシウム。 17.前記浸透性薬剤が、300mmol/Lまでの溶液を含む、請求項15に記載の腹膜 透析溶液。 18.以下を含む腹膜透析溶液: おおよそ1.0〜約40.0mmol/LのL−カルノシン; おおよそ0.0〜約300mmol/Lのブドウ糖; おおよそ100〜約150mmol/Lのナトリウム; おおよそ70〜約140mEq/Lの塩素; おおよそ0.0〜約45mEq/Lの乳酸塩; おおよそ0.0〜約45mEq/Lの重炭酸塩(B-carbonate); おおよそ0.0〜約4.0mEq/Lのカルシウム;および おおよそ0.0〜約4.0mEq/Lのマグネシウム。 19.慢性腎不全の患者を処置するための静脈注射溶液であって、以下を含む溶 液: L−カルノシン; おおよそ0〜約200mEq/Lのナトリウム; おおよそ0〜約100mEq/Lのカリウム; おおよそ0〜約300mEq/Lの塩素; おおよそ0〜約10mEq/Lのカルシウム; おおよそ0〜約10mEq/Lのマグネシウム; おおよそ0〜約20mmol/Lのリン酸塩; おおよそ0〜約100mEq/Lの重炭酸塩; おおよそ0〜約100mEq/Lの乳酸塩; おおよそ0〜約100mEq/Lの酢酸塩; おおよそ0〜約150g/Lのアミノ酸; おおよそ0〜約100g/Lのジペプチド;および おおよそ0〜約300g/Lの脂質。 20.前記溶液が、おおよそ1〜約80mmol/LのL−カルノシンを含む、請求項19 に記載の静脈注射溶液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/742,018 US6017942A (en) | 1996-10-31 | 1996-10-31 | Method and compositions for the treatment of renal failure |
US08/742,018 | 1996-10-31 | ||
PCT/US1997/018722 WO1998018467A1 (en) | 1996-10-31 | 1997-10-21 | Compositions for the treatment of renal failure, comprising l-carnosine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008264492A Division JP2009051850A (ja) | 1996-10-31 | 2008-10-10 | L−カルノシンを含む腎不全の処置用の組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000503326A true JP2000503326A (ja) | 2000-03-21 |
JP4364307B2 JP4364307B2 (ja) | 2009-11-18 |
Family
ID=24983173
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52053298A Expired - Fee Related JP4364307B2 (ja) | 1996-10-31 | 1997-10-21 | L―カルノシンを含む腎不全の処置用の組成物 |
JP2008264492A Pending JP2009051850A (ja) | 1996-10-31 | 2008-10-10 | L−カルノシンを含む腎不全の処置用の組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008264492A Pending JP2009051850A (ja) | 1996-10-31 | 2008-10-10 | L−カルノシンを含む腎不全の処置用の組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6017942A (ja) |
EP (1) | EP0869788B1 (ja) |
JP (2) | JP4364307B2 (ja) |
KR (1) | KR19990076920A (ja) |
BR (1) | BR9706908A (ja) |
CA (1) | CA2241458A1 (ja) |
DE (1) | DE69735162T2 (ja) |
WO (1) | WO1998018467A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE405277T1 (de) * | 1999-04-26 | 2008-09-15 | Edwards Lifesciences Ag | Substitutions-infusionflüssigkeit und zitratanticoagulation |
US7186420B2 (en) * | 1999-04-26 | 2007-03-06 | Edwards Lifesciences Corporation | Multi-part substitution infusion fluids and matching anticoagulants |
US8105258B2 (en) | 1999-04-26 | 2012-01-31 | Baxter International Inc. | Citrate anticoagulation system for extracorporeal blood treatments |
GB0017028D0 (en) * | 2000-07-11 | 2000-08-30 | Ks Biomedix Ltd | Peptides and their therapeutic use |
US7033498B2 (en) * | 2000-11-28 | 2006-04-25 | Renal Solutions, Inc. | Cartridges useful in cleaning dialysis solutions |
US6627164B1 (en) * | 2000-11-28 | 2003-09-30 | Renal Solutions, Inc. | Sodium zirconium carbonate and zirconium basic carbonate and methods of making the same |
US6878283B2 (en) * | 2001-11-28 | 2005-04-12 | Renal Solutions, Inc. | Filter cartridge assemblies and methods for filtering fluids |
SE0400523D0 (sv) * | 2004-03-01 | 2004-03-01 | Gambro Lundia Ab | A medical solution, a method for producing said medical solution and use thereof |
SE0402507D0 (sv) * | 2004-10-14 | 2004-10-14 | Gambro Lundia Ab | Medicinsk lösning, förfarande för framställning och användning därav |
CN101217960B (zh) * | 2005-07-08 | 2010-12-15 | 东丽株式会社 | 用于改善尿毒症的治疗药和处置方法 |
CA2698754A1 (en) * | 2007-09-11 | 2009-03-19 | Dorian Bevec | Use of a peptide as a therapeutic agent |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
TW201338803A (zh) * | 2012-03-23 | 2013-10-01 | zheng-yi Lin | 用於治療寵物腎衰竭之醫藥組合物 |
US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
EP2928461B1 (en) * | 2012-12-06 | 2019-08-21 | Bio Health Solutions, LLC | Treatment for chronic kidney disease |
AU2015231764B2 (en) | 2014-03-17 | 2017-02-09 | Fresenius Medical Care Holdings, Inc. | Cartridges useful in cleaning dialysis solutions |
CN108025125B (zh) | 2015-09-16 | 2021-05-07 | 弗雷塞尼斯医疗保健控股公司 | 在净化透析溶液中可用的药筒 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2936070A1 (de) * | 1979-09-06 | 1981-03-26 | Dr. Falk GmbH & Co Pharm. Präparate KG, 7800 Freiburg | Gallenwegespuelloesungen |
US4446149A (en) * | 1981-12-14 | 1984-05-01 | Kineshiro Nagai | Medicine for treatment of cervical erosion |
US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
-
1996
- 1996-10-31 US US08/742,018 patent/US6017942A/en not_active Expired - Fee Related
-
1997
- 1997-10-09 US US08/953,797 patent/US5968966A/en not_active Expired - Lifetime
- 1997-10-21 WO PCT/US1997/018722 patent/WO1998018467A1/en active IP Right Grant
- 1997-10-21 DE DE69735162T patent/DE69735162T2/de not_active Expired - Lifetime
- 1997-10-21 BR BR9706908A patent/BR9706908A/pt not_active Application Discontinuation
- 1997-10-21 JP JP52053298A patent/JP4364307B2/ja not_active Expired - Fee Related
- 1997-10-21 KR KR1019980705048A patent/KR19990076920A/ko not_active Application Discontinuation
- 1997-10-21 CA CA002241458A patent/CA2241458A1/en not_active Abandoned
- 1997-10-21 EP EP97911001A patent/EP0869788B1/en not_active Expired - Lifetime
-
2008
- 2008-10-10 JP JP2008264492A patent/JP2009051850A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US6017942A (en) | 2000-01-25 |
EP0869788B1 (en) | 2006-01-25 |
JP4364307B2 (ja) | 2009-11-18 |
US5968966A (en) | 1999-10-19 |
DE69735162D1 (de) | 2006-04-13 |
WO1998018467A1 (en) | 1998-05-07 |
CA2241458A1 (en) | 1998-05-07 |
BR9706908A (pt) | 1999-07-20 |
KR19990076920A (ko) | 1999-10-25 |
JP2009051850A (ja) | 2009-03-12 |
DE69735162T2 (de) | 2006-08-17 |
EP0869788A1 (en) | 1998-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009051850A (ja) | L−カルノシンを含む腎不全の処置用の組成物 | |
Mitzner et al. | Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial | |
EP0456806B1 (en) | Histidine buffered peritoneal dialysis solution | |
EP0716607B1 (en) | Biochemically balanced peritoneal dialysis solutions | |
US6214802B1 (en) | Peritoneal dialysis fluid | |
MXPA06014254A (es) | Soluciones para dialisis peritoneal a base de bicarbonato. | |
JPH08508300A (ja) | マルトデキストリン及びアミノ酸を含有する腹膜透析液 | |
JP2010150281A (ja) | イコデキストリンを含有する生体適合性透析液 | |
JP2005162767A (ja) | ポリペプチドを含んだ改良された腹膜透析液 | |
von Albertini et al. | Short hemodialysis | |
EP0914147B1 (en) | Atrial natriuretic peptide (anp) as an additive to peritoneal dialysis solutions | |
JP2000038348A (ja) | アルブミン含有腹膜透析液 | |
MXPA98005326A (en) | Compositions for the treatment of renal failure, comprising l-carnosine | |
Nissenson | Acid-base homeostasis in peritoneal dialysis patients | |
EP3452136A1 (en) | Dialysis concentrate | |
Agishi et al. | Artificial Organs: Thoughts & Progress: Orally Diluting Hemofiltration | |
Böhler | Treatment of acute renal failure in intensive care patients | |
TERATO et al. | Excretion of Creatinine into Gastrointestinal Tract in Renal-artery-ligated Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081010 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20081009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090624 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090811 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090819 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120828 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |